(Total Views: 678)
Posted On: 08/14/2025 11:10:46 PM
Post# of 155844
July 2025 past CRC Abstract printed:
"While >10 new therapies for metastatic colorectal cancer (mCRC) have been approved from 2010-2025, improvement in median overall survival (mOS) has only increased from 20 to 27 months and patients with relapsed mCRC currently have a mOS of 15 months, and 7.5 months for 2nd or 3rd therapies, respectively."
2 excerpt from Results:
1) and patients had received 1-3 prior systemic therapy lines for mCRC.
2) mOS from the first dose of leronlimab was 15.8 months
https://www.annalsofoncology.org/article/S092...7/fulltext
___
1 dose of Leronlimab was better than all relapsed mCRC lines.
Our current 700mg LL / ICI "Prime & Pair", will significantly change relapsed mCRC worldwide.
Still betting we announce a trial partnership for 1st & 2nd line CRC.
ICI mfgr's alone, will make sure LL makes it to market.
Leronlimab’s ROI will prove unprecedented.
For humanity & monetarily.
"While >10 new therapies for metastatic colorectal cancer (mCRC) have been approved from 2010-2025, improvement in median overall survival (mOS) has only increased from 20 to 27 months and patients with relapsed mCRC currently have a mOS of 15 months, and 7.5 months for 2nd or 3rd therapies, respectively."
2 excerpt from Results:
1) and patients had received 1-3 prior systemic therapy lines for mCRC.
2) mOS from the first dose of leronlimab was 15.8 months
https://www.annalsofoncology.org/article/S092...7/fulltext
___
1 dose of Leronlimab was better than all relapsed mCRC lines.
Our current 700mg LL / ICI "Prime & Pair", will significantly change relapsed mCRC worldwide.
Still betting we announce a trial partnership for 1st & 2nd line CRC.
ICI mfgr's alone, will make sure LL makes it to market.
Leronlimab’s ROI will prove unprecedented.
For humanity & monetarily.
(25)
(0)
